CLINICAL_TRIALS
trial_result
· 2021-03-15
Clinical Trial Update: A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) [Phase 3]
Summary
Phase 3 trial update for ALKS 5461 in treatment-refractory major depressive disorder completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alkermes, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2021-03-15